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1. Introduction 
Bloodless Medicine and Surgery (BMS) is the provision of quality health care to patients 
without the use of allogeneic blood with the aim of improving outcome and protecting 
patients’ rights.1, 2  It involves the use of Blood Conservation techniques in combinations that 
are specific to the individual patient, ideally following a protocol and a multidisciplinary 
approach, and is synonymous with Transfusion-free Medicine and Surgery.3, 4 
The term Patient Blood Management has crept into popular use in some circles, and has 
been recently defined by the Society for the Advancement of Blood Management as “the 
application of evidence-based medical and surgical concepts aimed at relying on a patient's 
own blood rather than on donor blood and achieving better patient outcomes”.5 The basic 
principles or ‘pillars’ of Patient Blood Management were ratified by the 63rd World Health 
Assembly, and are identical to those of BMS as discussed herein.6 
BMS has traditionally been considered in clinical situations where patients refuse blood, and 
when ‘safe’ blood is unavailable or in short supply.1  Many clinicians are surprised to learn 
that blood transfusion is based on tradition and associated with a poorer outcome 
(unrelated to infectious hazards) in a wide variety of patients.7  Today, BMS has emerged as 
the standard of care appropriate for all patients because it is evidence-based and associated 
with a better outcome.1, 2  
2. A brief history of bloodless medicine & surgery 
For about 2000 years up until the 19th century bloodletting rather than blood transfusion was 
the standard practice in medicine.8 Virtually all surgeries prior to the 20th century were 
essentially ‘bloodless’, and some were remarkably successful. Theodore Kocher, for 
instance, did his first thyroidectomy in 1872, and by the end of his career he had done 5000 
thyroidectomies with only 1% mortality. Kocher never transfused any patient and he won a 
Nobel Prize.9  
Karl Landsteiner’s discovery of the ABO blood groups in 1900 started off the modern era of 
transfusion medicine. In 1915 Richard Lewisohn introduced anticoagulation with sodium 
citrate. Blood transfusion was used for World War I and II military casualties. Bernard 
Fantus set up the first hospital based blood bank in Chicago, USA about 1937.10  From then 
on blood transfusion became a universal practice in medicine, so that the popular dictum 
seemed to be “When in doubt transfuse!”.3 
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BMS started as an attempt by some dedicated surgeons in the 1960s to accommodate 
patients who declined blood transfusion, notably Jehovah’s Witnesses.11, 12  Their religious 
belief is based on a distinctive interpretation of specific passages from the Bible, such as: 
“You are to abstain from … blood” – Acts Ch. 15 v. 29 (New English Bible)13, 14 
Denton Cooley, widely regarded as the founding father of modern bloodless surgery, 
performed the first bloodless open-heart surgery on one of Jehovah’s Witnesses on May 18th, 
1962.2, 12 In 1977 Ott and Cooley published a pioneer report of 542 open-heart surgeries 
without allogeneic blood transfusion in patients ranging in age from one day to 89 years,15  
demonstrating that the “impossible” was possible – and safer. Other surgeons joined, but 
their ingenious techniques did not gain wide acceptance then.2 
The advent of HIV/AIDS in 1981 forced a reconsideration of blood transfusion practices and 
a desire for BMS  on account of the epidemic proportions of HIV, and the fact that the surest 
(though not the commonest) route of transmission is through blood transfusion. Many other 
pathogens old and new that are transmitted by blood (Table 1),16 and many non-infectious 
hazards (Table 2)17 received renewed attention and prominence. The cost of making blood 
“safe” rose astronomically while the supply of “safe” blood shrank. This added further 
impetus to the search for transfusion alternatives and the promotion of blood conservation 
techniques.1, 2    
Recently however, the focus has shifted from the hazards of allogeneic blood to its efficacy – 
or lack of it. The Canadian Critical Care Trials Group study on Transfusion Requirements in 
Critical Care (TRICC) by Hérbert and co-workers in 1999 was a landmark prospective 
randomized study of 838 ICU patients comparing a liberal transfusion versus restricted 
transfusion policy. It revealed better results with the restricted transfusion group: lower ICU 
mortality, lower hospital mortality, lower 30-day mortality, and a trend towards decreased 
organ failure.18 Several other studies have confirmed adverse outcome in transfused patients 
not related to infectious hazards.19-24  Allogeneic blood has been found to increase 
hemorrhage, impair perfusion of the microcirculation, impair oxygen release from 
hemoglobin, and worsen rather than improve tissue oxygenation.25-29  Some of these effects 
are thought to be due to storage lesions. On the other hand, it has not been possible to 
demonstrate the benefits of RBC transfusion.7, 19, 29, 30 
Thus, while BMS started as an advocacy and then became widespread because of the 
infectious hazards and high cost/scarcity of allogeneic blood, Evidence-Based Medicine has 
recently emerged as the driving force behind its current practice, with improvement of 
outcome as the major aim. 
3. Blood conservation techniques 
Blood conservation techniques form the basis of the practice of BMS, and may be grouped 
under of four basic categories or “pillars”:3 
1. Optimizing the Hematocrit 
2. Minimizing blood loss 
3. Optimizing tissue oxygenation  
4. Lowering the ‘Transfusion Trigger’ (tolerance of anemia) 
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Viruses 
Hepatitis viruses 
Hepatitis A virus (HAV) 
Hepatitis B virus (HBV) 
Hepatitis C virus (HCV) 
Hepatitis D virus (HDV) (requires co-infection with HBV) 
Hepatitis E virus (HEV) 
Retroviruses 
Human immunodeficiency virus (HIV) 1 and +2 
(+ + other sub-types) 
Human T-cell leukemia virus (HTLV) I and II 
Herpes viruses 
Human cytomegalovirus (HCMV) 
Epstein–Barr virus (EBV) 
Human herpes virus 8 (HHV-8) 
Parvoviruses 
Parvovirus B19 
Miscellaneous viruses 
GBV-C [previously referred to as hepatitis G virus (HGV)] 
TTV 
West Nile virus 
Bacteria 
Endogenous 
Treponema pallidum (syphilis) 
Borrelia burgdorferi (Lyme disease) 
Brucella melitensis (brucellosis) 
Yersinia enterocolitica 
Salmonella spp. 
Exogenous (environmental species and skin commensals) 
Staphylococcal spp. 
Pseudomonas 
Serratia spp. 
Rickettsiae 
Rickettsia rickettsii (Rocky Mountain spotted fever) 
Coxiella burnettii (Q fever) 
Protozoa 
Plasmodium spp. (malaria) 
Trypanosoma cruzi (Chagas disease) 
Toxoplasma gondii (toxoplasmosis) 
Babesia microti/divergens (babesiosis) 
Leishmania spp. (leishmaniasis) 
Prions 
Variant Creutzfeldt–Jakob disease (vCJD) 
Table 1. Infectious agents transmissible by blood transfusion16 
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Immune mediated 
Hemolytic transfusion reactions 
Febrile nonhemolytic transfusion reactions 
Allergic/urticarial/anaphylactic transfusion reactions 
Transfusion-related acute lung injury (TRALI) 
Posttransfusion purpura (PTP) 
Transfusion-associated graft versus host disease (TA-GVHD) 
Microchimerism 
Transfusion-related immunomodulation (TRIM) 
Alloimmunization 
Nonimmune mediated 
Septic transfusion reactions 
Nonimmune hemolysis 
Mistransfusion 
Transfusion-associated circulatory overload (TACO) 
Metabolic derangements 
Coagulopathic complications from massive transfusion 
Complications from red cell storage lesions 
Over/undertransfusion 
Iron overload 
Table 2. Noninfectious Serious Hazards of Transfusion (NISHOTs)17 
Virtually all techniques of blood conservation are meant to buttress one or other of these 
pillars, and when used in combination they effectively reduce or eliminate the use of 
allogeneic blood with its costs and hazards, and improve clinical outcome (Table 3). 
3.1 Optimizing the hematocrit 
Optimizing the hematocrit increases the tolerable blood loss or the margin of safety in the 
event of blood loss in surgery, and reduces morbidity and mortality in non-surgical patients. 
Iron therapy is at the center of current efforts in this regard with or without Erythropoiesis 
Stimulating Agents (ESAs), even in the absence of absolute iron deficiency. 1,2, 31   
a. Oral Iron Therapy is the modality of choice for eligible patients. Ferrous sulfate, 
gluconate or fumarate may be used to administer ideally 200-220mg of elemental iron 
per day. Adjuncts to be given daily include Vitamin C 500mg, Vitamin B12 150µg, Folic 
Acid 5mg, Multivitamins, and nutritional support.4, 31 The author avoids folic acid in 
malignant disease.32 
b. Parenteral Iron Therapy corrects anemia more rapidly, and may be used alone or in 
conjunction with ESAs. Intravenous iron is also preferred in anemia of chronic disease  
Iron dextran is the classical preparation and a low molecular weight iron dextran is 
available. However, less allergenic preparations are currently favored, especially iron 
sucrose.31  Dose in mg = weight x [normal Hb – actual Hb (g/L)] x 0.24 + 500,31 or [normal 
Hb – actual Hb (g/dL)] x 200 + 500.4 
Iron dextran is diluted in normal saline at a ratio of 5ml (250mg):100mL saline and 
administered intravenously initially at 20 drops/min for 5 minutes, then 60 drops/min 
if no side effects occur. The total dose may be given at once to a maximum of 20mg/kg 
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body weight over 4-6 hours or in divided doses on alternate days (preferably).4, 31  The 
author found that administering Hydrocortisone 100mg i.v. 15 minutes before iron 
dextran, and diluting 5ml (250mg) of iron dextran in 250-500mL of normal saline 
successfully averts allergic reactions, even in a patient who previously reacted when 
those measures were not taken.31 
Iron sucrose is less allergenic and is also administered safely in normal saline infusion 
100mg:50mL or 200mg:100mL over 30 minutes, or 500mg:250mL administered over 3 
hours. The total dose may be given at once to a maximum of 7mg/kg body weight over 
3-3.5 hours (some workers have given 1000mg safely) or in divided doses on alternate 
days.4  
c. Erythropoietin alfa which was in use for blood conservation in oncology since 1989 
was approved for perioperative use in the US in 1996. Beta preparations are also 
available. In general surgery 100-150U/kg s.c. for 6 doses (e.g. twice weekly for 3 
weeks) is recommended.4  In oncology 150U/kg s.c. 3 times weekly or 40,000U s.c. 
weekly is the recommended starting dose.33  Darbopoietin alfa is a long-acting ESA 
that can be administered s.c. weekly (2.25µg/kg) or 3 weekly (500µg). Intravenous iron 
is recommended in conjunction with ESAs as it potentiates the response and averts 
functional iron deficiency.4, 34 
ESAs stimulate RBC production by up to 4 times the basal marrow rate. Reticulocyte 
count increases by Day 3 and hemoglobin typically increases at 1g/dL every 4-7 days.34  
Use of ESAs is not recommended when the hemoglobin is above 12g/dl in oncology.33  
Optimizing the hemoglobin with the appropriate medication is indicated in virtually all 
surgical patients, in elective and emergency cases, as it is in treatment and prophylaxis of 
anemia in non-surgical patients.4  Interventions in this regard do not start working slowly 
after 21 days as some may imagine, but start working immediately and build up over 
time.31, 34 Provided the main pathology is properly and promptly treated, the patient’s 
improvement with bloodless care is sometimes dramatic, compared with patients who are 
transfused. 
3.2 Minimizing blood loss 
Efforts towards minimizing blood loss in the surgical patient start from the first contact and 
span through the entire perioperative period. 
a. Good history, physical examination, and laboratory investigations are essential even 
in emergencies, taking note of the following among others: 
i. History of bleeding disorders 
ii. Anticoagulant therapy 
iii. Site of external hemorrhage (to be promptly arrested) 
iv. Estimate of blood loss 
v. Full Blood Count 
vi. Clotting profile (if indicated) 
b. Pharmacological agents that can reduce hemorrhage include:4 
i. Vitamin K 10mg (2.5-50mg) p.o., i.m., s.c., i.v. 
ii. Tranexamic acid 1.5g 3x/day – 1g 6x/day for 5-7 days, first i.v. then p.o. (for 
prophylaxis, 1g p.o. preop). 
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iii. Aprotinin 500,000KIU i.v. then 150,000KIU/h in infusion (low-dose regimen, for 
noncardiac surgery); or 2,000,000KIU i.v. then 2,000,000KIU in CPB prime, then 
500,000KIU in infusion for duration of surgery (Hammersmith high-dose regimen 
for cardiac surgery). 
iv. Epsilon Aminocaproic acid (EACA) 0.1g/kg i.v. over 30-60 min then 8-24g/day or 
1g every 4 hours. When bleeding stops, 1g 6 hourly. Same dosage can be given p.o. 
v. Desmopressin (1 –deamino-8-D-arginine vasopressin or DDAVP) 0.3µg/kg i.v. or 
s.c. x2 periop, second dose 6-8 hours after the first; or 2 intranasal “standard puffs” 
totaling 300µg for home use (e.g. menorrhagia), repeated as necessary after 8-12 
hours. 
vi. Recombinant Factor VIIa 90µg/kg i.v., repeat dose every 2-3 hours or as needed. 
vii. Somatostatin 
viii. Vasopressin 
ix. Misoprostol 600 µg p.o. to prevent postpartum hemorrhage  
c. Non-invasive monitoring such as pulse oximetry, whenever possible, minimizes blood 
loss. 
d. Restriction of diagnostic phlebotomies reduces blood wastage. Microsampling is a 
recent technique that drastically reduces the volume of blood needed for tests, with 
obvious benefits in blood conservation. 
e. Intraoperative strategies that could be employed to reduce blood loss include: 
i. Normothermia averts coagulopathy due to hypothermia,1, 4, 35  and may be 
achieved by  
1. Maintaining room temperature above 270 C 
2. Thermal suits or blankets 
3. Warming of intravenous infusions  
ii. Acute Normovolemic Hemodilution (ANH) involves withdrawal of some of the 
patient’s blood in the operating room prior to incision, and replacement with 
colloids and/or crystalloids, so that intraoperatively the patient loses dilute blood 
with less effect on the total red cell mass. The withdrawn blood is kept within view 
in the operating room and is re-infused at the end of surgery.  
 Up to 4 units may be withdrawn safely using the formula V = [Baseline HCT – 
Target HCT]/Average HCT x EBV. (V = volume, HCT = hematocrit, EBV = estimated 
blood volume).36 
iii. Regional anesthesia results in less intraoperative blood loss than general 
anesthesia through mechanisms not yet fully elucidated.4 
iv. Positioning of patients to minimise blood loss is guided by two principles:2 
1. Elevate the operation site above the right atrium e.g. Trendelenburg for 
prostatectomy, reverse Trendelenburg for thyroidectomy; 
2. Avoid compression of venous drainage e.g. tilting patient in supine position 
slightly to the left to avoid compression of inferior vena cava in abdominal 
surgery. 
v. Meticulous hemostasis and good operative technique can save up to 1 or more 
units of blood.1  Simple techniques like Pringle’s manoeuvre in liver surgery and B-
lynch suture in postpartum haemorrhage can be employed to great benefit. Use of 
diathermy and topical adhesives like fibrin glue and Surgicel® (Johnson & Johnson, 
Somerville, NJ, USA) limits blood loss, as does judicious use of tourniquet. Argon 
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Beam Coagulator and Cavitron Ultrasonic Surgical Aspirator (CUSA) are blood 
conserving innovations in hemostasis and dissection respectively.1, 4, 37   
vi. Cell salvage and autotransfusion can be performed effectively by techniques 
ranging from simple manual scooping of blood from a wound, filtration then re-
infusion, to use of sophisticated computerized cell salvage machines that return 
washed blood into the patient. 
vii. Laparascopic surgery and interventional radiology can effectively reduce blood 
loss in many surgical procedures. 
viii. Other techniques like controlled hypotension and hypothermia may be used 
cautiously in selected patients.2, 4 
 
Options 
Number of Units of 
blood conserved 
Preoperative 
Tolerance of anemia (lowering the transfusion trigger) 
Increasing preoperative RBC mass 
 
1-2 
2 
Intraoperative 
Meticulous hemostasis and operative technique 
ANH 
Blood salvage 
 
1 or more 
1-2 
1 or more 
Postoperative 
Restricted phlebotomy 
Blood salvage 
 
1 
1 
Table 3. Approximate contributions of selected modalities to blood conservation in the 
surgical patient (adapted from Goodnough et al, 20031) 
3.3 Optimizing tissue oxygenation 
This principle is often omitted from the “pillars” of BMS or Patient Blood Management.6, 7  
Nevertheless, it can be deduced as a separate and indispensable element since tissue 
oxygenation is the major function of blood.  
Many clinicians transfuse blood in the hope of improving the patient’s tissue oxygenation. 
However, allogeneic blood transfusion has been shown not to improve but to decrease 
tissue oxygenation.27-29 Rather, tissue oxygenation can be improved by other methods 
avoiding blood transfusion by considering the equation for oxygen delivery:38 DO2 = CO x 
CaO2 = CO x {(Hb x SaO2 x 1.39) + (PaO2 x 0.003)}. (DO2 = oxygen delivery, CO = cardiac 
output, CaO2 = arterial O2 content, Hb = hemoglobin concentration, SaO2 = fraction of 
hemoglobin saturated with O2, PaO2 = partial pressure of O2 dissolved in arterial blood). 
Thus, even when Hb is low, DO2 can be improved by improving the CO and CaO2 (SaO2 
and PaO2). 
a. Volume replacement with crystalloids (e.g. normal saline and Ringer’s lactate) or 
colloids (e.g. Hetastarch, Hemacel®, Dextran, and Isoplasma®) reduces blood viscosity 
and improves cardiac output. Crystalloid requirement is 3 times blood volume lost, 
while colloid requirement is equivalent to volume lost and is therefore preferable when 
there is danger of circulatory overload with crystalloids. 
www.intechopen.com
 
Blood Transfusion in Clinical Practice 
 
198 
b. Oxygen therapy increases SaO2 and PaO2. Intraoperative hyperoxic ventilation not only 
improves tissue oxygenation but also can augment ANH and avert allogeneic blood 
transfusion.2, 4  Hyperbaric oxygen is rarely needed but may be used when indicated 
and available.2, 4 
c. Minimizing oxygen consumption may be achieved through appropriate interventions 
such as: 
i. Adequate analgesia 
ii. Treatment of sepsis 
iii. Mechanical ventilation (to reduce the work of breathing) 
d. Treating causes of tissue hypoxia promptly e.g. pneumonia, bronchial asthma. 
e. Inotropic and vasoactive agents may be used in extreme cases to improve cardiac 
output. Low dose dopamine (2-5µg/kg/minute) also improves renal perfusion, but 
higher doses cause vasoconstriction. 
f. Artificial Oxygen carriers are still largely experimental. They include Perflourocarbon 
emulsions and modified hemoglobin-based solutions. They have been used successfully 
in Augmented ANH (A-ANH).2, 4   
3.4 Lowering the transfusion trigger (tolerance of anemia) 
Lowering the ‘transfusion trigger’ means accepting lower hemoglobin/hematocrit levels for 
treatment without blood transfusion. The “10/30” (hemoglobin/hematocrit) transfusion 
trigger employed for decades to dictate blood transfusion practices was based on a study in 
dogs by Adams and Lundy in 1942, and has been demonstrated not to be valid in humans. 
Lowering the transfusion trigger from 10g/dl to 7g/dl in critically ill patients in intensive 
care reduced red cell unit transfusions by 54% and improved clinical outcomes.2, 20   
The Association of Anaesthetists of Great Britain and Ireland affirms that “a haemoglobin 
concentration of 8-10 g.dL-1 is a safe level even for those patients with significant 
cardiorespiratory disease”.39  The current guidelines of The Society of Thoracic Surgeons 
and the Society of Cardiovascular Anesthesiologists suggests a transfusion trigger of 
hemoglobin less than 7g/dL.40  However, patients have survived with hemoglobin below 
3g/dl, and so currently there is no universal transfusion trigger.41   
4. Bloodless medicine and surgery programs 
Bloodless medicine and surgery programs (BMSPs) are specialized programs offering non-
blood treatment by a committed multidisciplinary staff to a wide variety of registered 
patients within a hospital setting. There are up to 240 of such programs worldwide.42  
Depending on the emphasis, various institutions have adopted various names for their 
program, such as Blood Conservation Program or Transfusion-Free Medicine Program. 
These programs provide the standard of care for patients without the use of allogeneic 
blood products. They invariably record superior results.2 
5. Newer innovations in bloodless medicine & surgery 
One of the selling points of robotic surgery is a drastic reduction in blood loss due to the 
increased precision obtainable (figure 1). 
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Non-invasive continuous monitoring of total hemoglobin is now possible with the Rainbow 
Pulse CO-Oximeter® by Masimo® Corporation (figure 2), licensed for use in the US in 2010. 
This is of great advantage during certain types of surgeries traditionally associated with 
much blood loss like cardiac surgery, liver surgery, and in monitoring ANH. 
 
Fig. 1. Robotic surgery 
 
Fig. 2. Pulse CO-Oximeter®  
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Thromboelastometry during cardiac surgery, liver transplantation and other similar 
surgeries has greatly reduced transfusion rates.43, 44 It monitors the coagulation status of the 
patient and greatly minimizes undue intervention with blood products. 
Plasmajet® by Plasma Surgical Limited is the product of newer technology for hemostasis 
during surgery (figure 3). It works in a similar manner to the argon beam coagulator. 
 
 
Fig. 3. Plasmajet® 
6. The future of bloodless medicine and surgery 
BMS is evidence-based.7  It results in faster recovery, lower morbidity, lower mortality, 
shorter hospital stay, lower cost and better patient (and physician) satisfaction.1, 2  
Furthermore, patient autonomy is respected and the hazards of allogeneic blood transfusion 
are avoided, in accordance with the principles of nonmaleficence and beneficence in the 
Hippocratic Oath.7, 41, 45  Understandably then, BMS is no longer an ‘alternative’ but the 
current standard of care.4  BMS may also be considered a crucial step in the journey towards 
universal ethical, scientific, and evidence-based practice of medicine.  
The Government of Western Australia is the first in the world to implement Patient Blood 
Management as an official policy starting from 2008.7  In 2010 the 63rd World Health 
Assembly of the World Health Organization officially recognized and adopted the “pillars” 
of Patient Blood Management.6  BMS is obviously therefore the universal standard of future 
ethical practice of medicine, having survived prejudice and being propelled by scientific 
evidence.  
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Blood conservation in BMS is not ‘a technique’ but a combination of techniques tailored to 
the needs and physiological status of the individual patient in order to avoid transfusion of 
allogeneic blood. It requires planning and a multidisciplinary team approach, but usually 
little technology, to achieve the best results. Setting up a BMSP with written protocols, 
standardizes the practice of bloodless medicine and surgery, thus ensuring that patients 
receive the best care. 
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